《IJCH,6月6日,Cardiovascular medications and regulation of Covid-19 receptors expression》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-06-07
  • Cardiovascular medications and regulation of Covid-19 receptors expression

    Author links open overlay panelNarjes SahebSharif-AskariaFatemeh SahebSharif-AskariaSabaAl HeialybeRifatHamoudiacTarekKashourdQutaybaHamidaceRabihHalwaniacf

    Show more

    https://doi.org/10.1016/j.ijchy.2020.100034

    Abstract

    Introduction

    Emerging epidemiological studies suggested that Renin–Angiotensin–Aldosterone system (RAAS) inhibitors may increase infectivity and severity of COVID-19 by modulating the expression of ACE2.

    Methods

    In silico analysis was conducted to compare the blood expression levels of SARS-CoV-2 entry genes between age and gender matched cohort of hypertensive patients versus control, and to determine the effect of common cardiovascular medications on the expression of Covid-19 receptors in vitro using primary human hepatocytes.

  • 原文来源:https://www.sciencedirect.com/science/article/pii/S2590086220300112
相关报告
  • 《6月6日_心血管药物与COVID-19受体表达的调节》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-06-07
    • 信息名称:心血管药物与COVID-19受体表达的调节 1.时间:2020年6月6日 2.机构或团队:沙迦大学、穆罕默德•本•拉希德大学等 3.事件概要: 沙迦大学等于6月6日在International Journal of Cardiology Hypertension期刊上发表题为“Cardiovascular medications and regulation of Covid-19 receptors expression”的文章。文章指出,新兴流行病学研究表明,肾素-血管紧张素-醛固酮系统(RAAS)抑制剂可能通过调节ACE2的表达来增强COVID-19的感染性和严重性。研究人员通过计算机分析,比较高血压患者与对照组人群之间SARS-CoV-2侵入基因的血液表达水平,并利用原代人肝细胞确定常用心血管药物对体外COVID-19受体表达的影响。文章最后得出结论,ACE2表达水平的提高可能是由于长期使用RAAS抑制剂、其他高血压相关因素或其他并发症引起。常见并发症的治疗往往需要长期使用多种药物,这可能导致ACE2和TMPRSS2的表达量增加。作者还指出,数据表明,需要更多的研究来确定不同药物以及药物组合对COVID-19受体的影响。 4.附件: 原文链接: https://www.sciencedirect.com/science/article/pii/S2590086220300112
  • 《CID,6月5日,100 Days of COVID-19 Prevention and Control in China》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-06-07
    • 100 Days of COVID-19 Prevention and Control in China Lei Zhou, M.D, Zunyou Wu, Ph.D, Zhongjie Li, M.D, Yanping Zhang, M.D, Jennifer M McGoogan, Ph.D, Qun Li, M.D, Xiaoping Dong, Ph.D, Ruiqi Ren, M.D, Luzhao Feng, Xiaopeng Qi Clinical Infectious Diseases, ciaa725, https://doi.org/10.1093/cid/ciaa725 Published: 05 June 2020 Article history Abstract The epidemic of novel coronavirus diseases was first reported in China in late December 2019 and has been brought under control after some two months in China. However, it has become a global pandemic and the number of cases and deaths continues to increase outside of China. We describe the emergence of the pandemic, detail the first 100 days of China’s response as a Phase 1 Containment followed by Phase 2 Containment strategy, and briefly highlight areas of focus for the future. Specific, simple, and pragmatic strategies used in China for risk assessment, prioritization, and deployment of resources are described. Details of implementation, at different risk levels, of the traditional public health interventions are shared. Involvement of society in mounting a whole country response and challenges experienced with logistics and supply chains are described. Finally, the methods China is employing to cautiously re-start social life and economic activity are outlined.